Clinical Trial Update: Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating adverse events and changes in disease activity in adults with advanced Parkinson's disease receiving ABBV-951 via a 24-hour continuous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ABBV-951

Snippet

Sponsor: AbbVie | Conditions: Parkinson's Disease (PD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING